Committed, tireless, and persistent.
We are committed to the discovery, development, and commercialization of a transformational generation of targeted therapies for women’s cancers.
Our team spent more than a decade conducting research, and has a deep insight into, endocrine-driven cancers. OP-1250 was the result of that persistence–the first compound designed to realize the Olema vision.